Trial of minocycline in a clinically isolated syndrome of multiple sclerosis

New England Journal of Medicine

Volumn 376, Issue 22, 2017, Pages 2122-2133

  Metz, Luanne M ^a,n   Li, David K B ^b   Traboulsee, Anthony L ^b   Duquette, Pierre ^c   Eliasziw, Misha ^m   Cerchiaro, Graziela ^a   Greenfield, Jamie ^a   Riddehough, Andrew ^b   Yeung, Michael ^a   Kremenchutzky, Marcelo ^d   Vorobeychik, Galina ^e   Freedman, Mark S ^f   Bhan, Virender ^g   Blevins, Gregg ^h   Marriott, James J ⁱ   Grand'Maison, Francois ^j   Lee, Liesly ^k   Thibault, Manon ^l   Hill, Michael D ^a   Yong, V Wee ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e Fraser Health MS Clinic   (Canada)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g DALHOUSIE UNIVERSITY   (Canada)

^h UNIVERSITY OF ALBERTA   (Canada)

ⁱ UNIVERSITY OF MANITOBA   (Canada)

^j Clinique Neuro Rive Sud   (Canada)

^k UNIVERSITY OF TORONTO   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m TUFTS UNIVERSITY   (United States)

ⁿ FOOTHILLS HOSPITAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; GLUCOCORTICOID; MINOCYCLINE; PLACEBO; TRIACYLGLYCEROL LIPASE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BACKACHE; CANADA; COLON CANCER; CONTROLLED STUDY; DEMYELINATING DISEASE; DISEASE COURSE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROENTERITIS; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERPIGMENTATION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RISK REDUCTION; SIDE EFFECT; THORAX PAIN; TOOTH DISCOLORATION; TREATMENT OUTCOME; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VAGINA CANDIDIASIS; WOUND INFECTION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; DEMYELINATING DISEASES; DIAGNOSTIC IMAGING; INTENTION TO TREAT ANALYSIS; LIFE TABLE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RISK; STATISTICAL ANALYSIS;

ACTUARIAL ANALYSIS; ADMINISTRATION, ORAL; ADULT; ANTI-BACTERIAL AGENTS; DEMYELINATING DISEASES; DISEASE PROGRESSION; DIZZINESS; DOUBLE-BLIND METHOD; EXANTHEMA; FEMALE; HUMANS; INTENTION TO TREAT ANALYSIS; LIFE TABLES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MINOCYCLINE; MULTIPLE SCLEROSIS; RISK; TOOTH DISCOLORATION;

EID: 85020036218     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1608889     Document Type: Article

References (24)

1. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM. The promise of minocycline in neurology. Lancet Neurol 2004; 3: 744-51.
2. Chen X, Ma X, Jiang Y, Pi R, Liu Y, Ma L. The prospects of minocycline in multiple sclerosis. J Neuroimmunol 2011; 235: 1-8.
3. Brundula V, Rewcastle NB, Metz LM, Bernard CC, Yong VW. Targeting leukocyte MMPs and transmigration: minocycline as a novel therapy for multiple sclerosis. Brain 2002; 125: 1297-308.
4. Popovic N, Schubart A, Goetz BD, Zhang SC, Linington C, Duncan ID. Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 2002; 51: 215-23.
5. Garner SE, Eady A, Bennett C, Newton JN, Thomas K, Popescu CM. Minocycline for acne vulgaris: efficacy and safety. Cochrane Database Syst Rev 2012; 8: CD002086.
6. Cunha BA. New uses for older antibiotics: nitrofurantoin, amikacin, colistin, polymyxin B, doxycycline, and minocycline revisited. Med Clin North Am 2006; 90: 1089-107.
7. Metz LM, Zhang Y, Yeung M, et al. Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2004; 55: 756.
8. Metz LM, Li D, Traboulsee A, et al. Glatiramer acetate in combination with minocycline in patients with relapsing-remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial. Mult Scler 2009; 15: 1183-94.
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann Neurol 2005; 58: 840-6.
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292-302.
11. Kang H, Metz LM, Traboulsee AL, et al. Application and a proposed modification of the 2010 McDonald criteria for the diagnosis of multiple sclerosis in a Canadian cohort of patients with clinically isolated syndromes. Mult Scler 2014; 20: 458-63.
12. Beck RW, Chandler DL, Cole SR, et al. Interferon beta-1a for early multiple sclerosis: CHAMPS trial subgroup analyses. Ann Neurol 2002; 51: 481-90.
13. Product monograph, apo-minocycline. Weston, ON, Canada: Apotex, 1994 (https://pdf.hres.ca/dpd-pm/00023208.PDF).
14. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsingremitting multiple sclerosis. Ann Neurol 1999; 46: 197-206.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444-52.
16. Common terminology criteria for adverse events v3.0 (CTCAE). Bethesda, MD: Cancer Therapy Evaluation Program, August 9, 2006 (http://ctep.cancer.gov/protocol Development/electronic-applications/docs/ctcaev3.pdf).
17. iDataFax website, 2016 (http://www.datafax.com/software/idatafax/).
18. Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 2009; 338: b2393.
19. James KE, Bloch DA, Lee KK, Kraemer HC, Fuller RK. An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation - a VA cooperative study. Stat Med 1996; 15: 1421-34.
20. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-9.
21. Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012; 11: 33-41.
22. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, doubleblind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13: 977-86.
23. Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol 2014; 13: 257-67.
24. Cree BA. Demyelinating disease: is TOPIC the last trial for clinically isolated syndrome? Nat Rev Neurol 2015; 11: 6-7.